Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
The Company has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a Wholly Owned Subsidiary of the Company and consequently, Bremer ceased to be a subsidiary of the Company. Shareholding for the Period Ended March 31, 2018
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here The Company Shall Submit The Audited Financial Results For The Year Ended On March 31, 2018 Within 60 Days From The End Of The Financial Year.
The Company shall submit the audited financial results for the year ended on March 31, 2018 within 60 days from the end of the financial year. Compliance Certificate For The Half Year Ended On March 31, 2018
Compliance Certificate for the half year ended on March 31, 2018 Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1340 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer Cadila Healthcare stock: Analysts see 20% compounded growth in US sales
While analysts have cut their forward net profit estimates to factor in the challenges, the correction in stock prices, according to them, is exaggerated Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare's Topical facility successfully completes USFDA inspection Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramanbhai B Patel HUF